Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 3Other solid neoplasm 2Genitourinary 2Breast 2Sarcoma 1Other hematologic neoplasm 1Other 1Lymphoid 1Endocrine 1Dermatologic 1CNS 1

Conditions

Skin Neoplasms 1Melanoma 1Gastrointestinal Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Aromatherapy × Endocrine × Clear all
NCT03858855 2020-08-04

Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment

Ohio State University Comprehensive Cancer Center

Phase NA Completed
248 enrolled
DermatologicEndocrineGastrointestinal

Gastrointestinal Neoplasms, Melanoma, Skin Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡